Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Guiding Comparative Effectiveness Research–A US Perspective

An interview between Howard Birnbaum (of Analysis Group, Inc., and Guest Co-Editor of this Special Issue) and Jean R. Slutsky (Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality)

    This is a preview of subscription content, log in to check access.

    References

    1. 1.

      Medicare Prescription Drug, Improvement, and Modernization Act of 2003, 108th Cong

    2. 2.

      American Recovery and Reinvestment Act of 2009, HR1,111th Cong

    3. 3.

      Gliklich RE, Dreyer NA, editors. Registries for evaluating patient outcomes: a user’s guide [prepared by Outcome DEcIDECenter (Outcome Sciences, Inc. dba Outcome) under Contract no. HHSA29020050035I TO1; AHRQ publication no. 07-EHC001-1]. Rockville (MD): Agency for Healthcare Research and Quality, 2007 Apr

    4. 4.

      US National Library of Medicine. Fact sheet: the National Library ofMedicine [online]. Available from URL: http://www.nlm.nih.gov/pubs/factsheets/nlm.html [Accessed 2010 May 7]

    5. 5.

      Atkins D, Siegel J, Slutsky J. Making policy when the evidence is in dispute. Health Aff 2005; 24 (1): 102–13

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Guiding Comparative Effectiveness Research–A US Perspective. Pharmacoeconomics 28, 839–842 (2010). https://doi.org/10.2165/11535800-000000000-00000

    Download citation

    Keywords

    • Peptic Ulcer Disease
    • Comparative Effectiveness Research
    • Make Policy Decision
    • Specific Clinical Question
    • Policy Controversy